One versus 2 years of alendronate following denosumab: the CARD extension
Osteoporosis International · 2024-12 · 35 (12) · 2225-2230
DOI: 10.1007/s00198-024-07213-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Osteoporosis International, online erschienen am 07.08.2024. Verfasst von Joy N Tsai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA. jntsai@mgh.harvard.edu. Hauptthemen laut MEDLINE: Denosumab, Alendronate, Bone Density Conservation Agents, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA. jntsai@mgh.harvard.edu.
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
- Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
Zitieren
APA
Tsai, J. N., Jordan, M., Lee, H., & Leder, B. Z. (2024). One versus 2 years of alendronate following denosumab: the CARD extension. Osteoporosis International, 35(12), 2225-2230. https://doi.org/10.1007/s00198-024-07213-2
Vancouver
Tsai JN, Jordan M, Lee H, Leder BZ. One versus 2 years of alendronate following denosumab: the CARD extension. Osteoporosis International. 2024;35(12):2225-2230. doi:10.1007/s00198-024-07213-2
BibTeX
@article{Tsai2024,
author = {Tsai, Joy N and Jordan, Mackenzie and Lee, Hang and Leder, Benjamin Z},
title = {One versus 2 years of alendronate following denosumab: the CARD extension},
journal = {Osteoporosis International},
year = {2024},
volume = {35},
number = {12},
pages = {2225--2230},
doi = {10.1007/s00198-024-07213-2}
}
EUVIMED